Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Meclizine
Drug ID BADD_D01361
Description Meclizine is a histamine H1 antagonist with antiemetic and antivertigo properties. It is used in the symptomatic treatment of motion sickness and control of vertigo associated with vestibular system diseases. It also exhibits anticholinergic, central nervous system depressant, and local anesthetic effects.[L6760] Commonly marketed under the brand name Antivert in the U.S., meclizine is available as oral tablets.
Indications and Usage Indicated for the symptomatic treatment of nausea, vomiting, and dizziness associated with motion sickness,[L6772] and management of vertigo due to various causes, including radiation sickness, Meniere’s syndrome, labyrinthitis and other vestibular disturbances.[L6766]
Marketing Status approved
ATC Code R06AE05
DrugBank ID DB00737
KEGG ID D08163
MeSH ID D008468
PubChem ID 4034
TTD Drug ID D0T1XW
NDC Product Code 71554-010; 51927-0043; 50268-522; 71335-0732; 0904-6516; 65162-441; 0615-8303; 70518-1402; 67763-116
UNII 3L5TQ84570
Synonyms Meclizine | Parachloramine | Meclozine | Antivert | Bonamine | Bonine | Chiclida | Histametizyn | Meclizine Hydrochloride | Hydrochloride, Meclizine | Meclizine Dihydrochloride | Dihydrochloride, Meclizine | Meclizine Monohydrochloride | Monohydrochloride, Meclizine | Ru-Vert-M | Ru Vert M | Agyrax | D-Vert | D Vert | DVert
Chemical Information
Molecular Formula C25H27ClN2
CAS Registry Number 569-65-3
SMILES CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Asthenia08.01.01.001--Not Available
Completed suicide19.12.01.001; 08.04.01.0100.000060%Not Available
Depression19.15.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000511%
Drug hypersensitivity10.01.01.0010.000511%Not Available
Drug ineffective08.06.01.0060.001112%Not Available
Dry mouth07.06.01.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema23.03.06.001--Not Available
Face oedema10.01.05.002; 23.04.01.004; 08.01.07.003--
Fatigue08.01.01.002--
Feeling hot08.01.09.009--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Oedema14.05.06.010; 08.01.07.006--Not Available
Oligohydramnios18.05.01.0010.000060%Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Petechiae01.01.03.002; 24.07.06.004; 23.06.01.003--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Somnolence19.02.05.003; 17.02.04.006--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.0030.000204%
Vision blurred17.17.01.010; 06.02.06.007--
The 1th Page    1 2    Next   Last    Total 2 Pages